RGC Description — Regencell Bioscience Holdings Ltd
Regencell Bioscience is a holding company. Through its subsidiaries, Co. is an early-stage bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder, and infectious diseases affecting people's immune system such as COVID.
Regencell Bioscience Holdings Ltd
Drugs & Pharmaceuticals
Number of ETFs Holding RGC:
Total Market Value Held by ETFs:
Total Market Capitalization:
% of Market Cap. Held by ETFs:
ETFs Holding RGC | Regencell Bioscience Holdings Ltd | ETF Channel | www.ETFChannel.com
Copyright © 2010 - 2022, All Rights Reserved
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.